Article3 Biotech2025
pH-responsive silica nanocarriers of olaparib for augmenting anticancer activity: development, characterization, and in vitro cytotoxicity study against MCF-7 breast cancer cells.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancing Olaparib's anti-cancer potential using nanostructured lipid carriers: formulation, evaluation, and in-vitro biological impact.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study focuses on the development and assessment of innovative chitosan-grafted silica nanocarriers encapsulating the PARP inhibitor, olaparib, designed for targeted delivery in breast cancer cells. The formulation aims to enhance therapeutic precision and efficacy in cancer treatment. Silica nanocarriers (SNs) were synthesized through a sol-gel method and subsequently coated with chitosan, employing GPTMS as a coupling agent. Olaparib (Ola) was successfully incorporated into the chitosan grafted silica nanocarriers (Ola-Ch-SNs). The resulting nanocarriers were characterized using techniques such as XRD, TEM, DLS, and TGA-DSC. Drug release profiles were evaluated in PBS across different pH conditions, while cytotoxicity was measured using the SRB assay in MCF-7 breast cancer cells. Uniform, pH-sensitive olaparib-loaded chitosan-coated silica nanocarriers (Ola-Ch-SNs) were successfully synthesized and characterized using advanced techniques including SEM, TEM, TGA, DSC, and XRD. The nanocarriers demonstrated excellent stability, achieving a drug loading efficiency of 44.31 ± 0.21% and an encapsulation efficiency of 83.12 ± 0.08%. Distinct pH-responsive drug release behavior was observed, with cumulative olaparib release reaching 57.6 ± 0.34% at pH 4.0 and 47.3 ± 0.02% at pH 6.0 over 24 h, compared to 22.6 ± 0.14% at pH 7.4 over 72 h. Release kinetics, described by the Korsmeyer-Peppas model, indicated a mechanism driven by both diffusion and polymer relaxation. In vitro cytotoxicity assays on MCF-7 breast cancer cells revealed enhanced anticancer activity of Ola-Ch-SNs compared to free olaparib, achieving a GI₅₀ value below 10 µg/ml and reducing cell viability to 23.4 ± 0.3% at 80 µg/ml. These findings underscore the potential of Ola-Ch-SNs as an innovative, targeted drug delivery system for effective cancer therapy. We successfully developed pH-responsive chitosan-coated silica nanocarriers loaded with olaparib, showcasing remarkable cytotoxicity against breast cancer cells. This formulation holds promise for enhancing olaparib bioavailability and advancing targeted cancer therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.